CN-121975691-A - Lactobacillus plantarum with high folic acid production capacity and application thereof

Abstract

The invention belongs to the technical field of microbial medicines, and discloses lactobacillus plantarum with high folic acid production capacity and application thereof. The lactobacillus plantarum is preserved in China Center for Type Culture Collection (CCTCC) with the preservation number of M20252434 and the classification name of Lactiplantibacillus plantarum P, and the 16S rDNA gene sequence of the lactobacillus plantarum is shown as SEQ ID NO. 1. The lactobacillus plantarum provided by the invention has the characteristics of high folic acid yield, strong antioxidant activity and high-efficiency removal of various free radicals, and in addition, the strain also has excellent acid resistance, bile salt resistance, automatic agglutination capability and antibacterial performance. Researches show that the lactobacillus plantarum can relieve hyperhomocysteinemia to a certain extent and improve related complications (including heart, intestinal canal and liver injuries), can be widely applied to food, health-care products or medicine production, and has a broad prospect.

Inventors

• XU HENGYI
• DAI WEN
• JIA TIANTIAN
• GUO JIAJUN
• WANG YUCHENG
• Peng Beini
• YU WENLE

Assignees

• 南昌大学

Dates

Publication Date

20260505

Application Date

20260130

Claims (10)

1. 1. The lactobacillus plantarum is characterized by being preserved in China Center for Type Culture Collection (CCTCC) with the preservation number of M20252434, and classified and named Lactiplantibacillus plantarum P133, and the 16S rDNA gene sequence of the lactobacillus plantarum is shown as SEQ ID NO. 1.
2. 2. The lactobacillus plantarum according to claim 1, wherein the folic acid producing ability of the strain is not less than 2.11 μg/mL.
3. 3. The lactobacillus plantarum according to claim 1, wherein the clearance of the strain to DPPH is 67.19 +/-1.36%, the clearance of hydroxyl radicals is 74.63 +/-1.02% and the reduction capacity is 2522+/-11.49 μmol/L of ascorbic acid reduction equivalent.
4. 4. The lactobacillus plantarum of claim 1, wherein the strain is isolated from a pickled cabbage.
5. 5. The Lactobacillus plantarum strain according to claim 1, wherein the strain is cultured in MRS liquid medium at 37℃for 24-36h while maintaining pH at 3.1-3.5, and the strain has an autoproteolysis capacity of 66.64.+ -. 0.93% after 24h of culture.
6. 6. The lactobacillus plantarum according to claim 1, wherein the strain has an inhibitory effect on a plurality of pathogenic bacteria including shigella, pseudomonas aeruginosa, escherichia coli O157, candida albicans and staphylococcus aureus, and the diameter of the inhibition zone is up to 31.67+/-3.21 mm.
7. 7. Use of the lactobacillus plantarum of claim 1 in the preparation of food or health care products.
8. 8. Use of lactobacillus plantarum according to claim 1 for the preparation of a medicament for the prevention and/or treatment of hyperhomocysteinemia and related complications.
9. 9. The use according to claim 7 or 8, wherein the effective concentration of lactobacillus plantarum is 10 8 -10 9 CFU/mL.
10. 10. A biological agent comprising at least one of a viable bacteria, an inactivated bacteria, an extracellular metabolite, or an intracellular extract of lactobacillus plantarum of claim 1.

Description

Lactobacillus plantarum with high folic acid production capacity and application thereof Technical Field The invention relates to the field of microbial medicines, in particular to lactobacillus plantarum with high folic acid production capacity and application thereof. Background Hyperhomocysteinemia (hyperhomocysteinemia, hhcy) refers to elevated levels (> 15. Mu. Mol/L) of homocysteine (Hcy) in the blood. Is closely related to various diseases and is an independent risk factor for cardiovascular diseases. Studies have shown that elevated homocysteine in both light and moderate levels increases the risk of cardiovascular death by a factor of 4-6. Hyperhomocysteinemia is a relatively common health problem and constitutes a major threat to cardiovascular health. The pathogenesis of hyperhomocysteinemia is complex, involving a number of factors. Possibly caused by a deficiency in related enzymes in the homocysteine metabolic process, the deficiency of B vitamins also affects homocysteine metabolism, resulting in its accumulation in the body. Unhealthy lifestyles, as well as other diseases and drugs, may also lead to hyperhomocysteinemia. The treatment means of hyperhomocysteinemia mainly comprises B vitamins such as folic acid and the like for medical treatment, food rich in folic acid such as green vegetables, beans and the like for eating, and combined medicine treatment for improving eating habits and the like. In general, folic acid is considered to be the most dominant regulator affecting homocysteine levels. Therefore, reasonable supplementation of folic acid is an effective measure for controlling homocysteine levels, preventing and treating related diseases. Folic acid (Folate) belongs to vitamin B and cannot be synthesized by human body. Folic acid is used as a cofactor to participate in various metabolism of the human body. The life activities of human beings are not separated from folic acid, and the deficiency of folic acid can cause various diseases, such as osteoporosis, poor cognitive ability, hyperhomocysteinemia and the like. The forms of folic acid supplementation mainly comprise two forms, namely chemical synthesis folic acid supplementation and natural folic acid supplementation of dietary sources. Studies have found that excessive intake of synthetic folic acid is detrimental, such as masking vitamin B12 deficiency and altering liver dihydrofolate reductase activity. In contrast, naturally derived folic acid is safer, but plant derived folic acid is subject to time constraints, and has the disadvantage of higher loss rate during cooking. Thus, it is necessary to supplement natural folic acid by other means. For example, folic acid obtained by a microbiological method has high quality and has no side effect on human bodies. Lactic acid bacteria are a generic term for a class of gram-positive bacteria that do not produce spores, are negative for catalase, and can utilize carbohydrates to produce lactic acid. It is widely distributed in nature, is often applied to the fields of industry, food and biological medicine, and is closely related to human health. The folic acid from lactic acid bacteria has the advantages of high safety, good absorption effect, no toxic or side effect and the like, can supplement folic acid and provide other nutrients required by organisms, and can not influence the bioavailability of the folic acid even under the condition of metabolic function defects of the organisms. In addition, lactic acid bacteria can also play a role in synergistic protection by rebalancing intestinal flora and regulating metabolic homeostasis of the body. Therefore, screening a strain of high-folate-producing lactic acid bacteria is critical for alleviating the health problems associated with hyperhomocysteinemia. Disclosure of Invention In order to solve the problems, the invention provides lactobacillus plantarum with high folic acid production capacity and application thereof. The lactobacillus plantarum is classified and named Lactiplantibacillus plantarumP and separated from pickled Chinese cabbage, can produce folic acid with high oxidation resistance and remove various free radicals with high efficiency, and can be widely applied to food, health care products or medicine production. In order to achieve the above purpose, the invention provides a lactobacillus plantarum which is preserved in China Center for Type Culture Collection (CCTCC) NO: M20252434, classified and named Lactiplantibacillus plantarumP133, and the 16S rDNA gene sequence of the strain is shown as SEQ ID NO: 1. Further, the folic acid production capacity of the strain is more than or equal to 2.11 mug/mL. Further, the clearance of the strain to DPPH is 67.19 +/-1.36%, the clearance of hydroxyl radicals is 74.63 +/-1.02%, and the reduction capacity is 2522+/-11.49 mu mol/L of ascorbic acid reduction equivalent. Further, the strain is isolated from a self-growing pickled Chinese cabbage, preferably a farmhouse-made p